- Yuhan Corp reported a parent operating profit of 15.73 billion won for the second quarter of 2024.
- Parent sales for the same period reached 514.63 billion won.
- Net profit for Yuhan Corp‘s parent company stood at 24.53 billion won.
- Market analysts provided their recommendations: 22 buys, 1 hold, and 1 sell.
A look at Yuhan Corp Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 2 | |
Growth | 3 | |
Resilience | 4 | |
Momentum | 5 | |
OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Yuhan Corp seems to have a promising long-term outlook. The company received a high score of 5 for Momentum, indicating strong positive price trends that may continue in the future. This suggests that investors are bullish on Yuhan Corp‘s stock performance. Additionally, Yuhan Corp scored a 4 for Resilience, highlighting the company’s ability to weather economic downturns and maintain stability. With a Growth score of 3, Yuhan Corp shows potential for expansion and increasing market share. Although the Value and Dividend scores are lower at 2 each, the overall outlook for Yuhan Corp appears to be positive, especially considering its diverse product portfolio.
Yuhan Corporation is a renowned manufacturer of various pharmaceutical products, personal care items, dietary supplements, and veterinary medicines. The company operates independently and collaborates with global pharmaceutical firms through joint ventures. With its strong presence in the pharmaceutical industry, Yuhan Corp is well-positioned for growth and resilience, as reflected in its Smartkarma Smart Scores. Investors may find Yuhan Corp an attractive long-term investment opportunity given its favorable momentum, resilience, and growth potential. The company’s commitment to innovation and diverse product offerings further enhance its position in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars